Cambrex is investing $3.6 million at its Karlskoga, Sweden facility to increase flexible drug substance manufacturing capacity. The work, which will convert a previously customer-dedicated manufacturing train, will include an additional production line at 6 m³ scale, resulting in a 25 percent capacity increase at the facility. Engineering work began and is expected to be completed by November 2020. The work involves modification of an existing 4 reactor configuration and the installation of ...